Glatiramer Acetate
Treatment for Multiple sclerosis
Typical Dosage: 20mg subcutaneous daily or 40mg subcutaneous three times a week
Effectiveness
70%
Safety Score
60%
Clinical Trials
108
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
20mg subcutaneous daily or 40mg subcutaneous three times a week
Time to Effect
6-12 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$65,000
Monitoring:$2,500
Side Effect Mgmt:$200
Total Annual:$67,700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$104,153.85
Cost per Remission
$338,500
Glatiramer Acetate Outcomes
for Multiple sclerosis
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+65%
Remission Rate
+20%
Common Side Effects
Injection site reactions
+40%
Vasodilation (flushing)
+20%
Post-injection reaction (flushing, chest pain, palpitations)
+18%
Rash
+16%
Dyspnea
+14%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Glatiramer Acetate in Multiple sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
NCT00819195COMPLETED
17 participants
OBSERVATIONAL
San Francisco, United States
Started: Dec 1, 2008
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
NCT03209479COMPLETED
1.33K participants
OBSERVATIONAL
Tokyo, Japan
Started: Nov 24, 2015
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
NCT00666224COMPLETEDPHASE3
481 participants
INTERVENTIONAL
Started: Jan 1, 2004
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
NCT04928313COMPLETED
368 participants
OBSERVATIONAL
Started: Apr 12, 2015
Safety of New Formulation of Glatiramer Acetate
NCT00947752COMPLETEDPHASE3
147 participants
INTERVENTIONAL
Started: Jul 1, 2009
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203021COMPLETEDPHASE4
208 participants
INTERVENTIONAL
Los Angeles, United States +10 more
Started: Mar 26, 1994
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
NCT01569451COMPLETEDPHASE2
53 participants
INTERVENTIONAL
Aurora, United States
Started: Feb 1, 2012
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
NCT01167426COMPLETEDPHASE3
148 participants
INTERVENTIONAL
Started: Jul 1, 2010
Efficacy and Safety of GTR in Comparison to Copaxone®
NCT01489254COMPLETEDPHASE3
794 participants
INTERVENTIONAL
Irvine, United States +132 more
Started: Oct 1, 2011
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
NCT00937157COMPLETEDNA
12 participants
INTERVENTIONAL
Buffalo, United States
Started: Sep 1, 2007
FOCUS Fatigue Outcome in Copaxone USers
NCT00267319COMPLETEDPHASE4
111 participants
INTERVENTIONAL
Prague, Czechia
Started: Jun 1, 2003
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
NCT02499900COMPLETEDPHASE4
861 participants
INTERVENTIONAL
Cullman, United States +96 more
Started: Aug 10, 2015
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
NCT03315923COMPLETEDPHASE2, PHASE3
84 participants
INTERVENTIONAL
Isfahan, Iran
Started: Dec 1, 2017
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
NCT00337779COMPLETEDPHASE3
1.16K participants
INTERVENTIONAL
Started: Aug 1, 2006
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
NCT00203112COMPLETEDPHASE2
44 participants
INTERVENTIONAL
Started: Jun 1, 2004
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
NCT02753088COMPLETEDPHASE3
158 participants
INTERVENTIONAL
Started: Oct 1, 2013
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
NCT00202982COMPLETEDPHASE2
90 participants
INTERVENTIONAL
La Jolla, United States +19 more
Started: Aug 1, 2003
Showing 20 of 108 total trials